Collaborative efforts for greater influence
As a venture studio, we aim to forge partnerships with academic, life-science or commercial entities to provide them with capital and insight for tailored support in drug development.
With precise focus in opportunities that are of strategic interests to Xentria, we offer our partners holistic support and enhanced operational efficiency.
This concentration of effort ideally positions our team to evaluate potential drug opportunities in an honest and authentic way.
The following projects are in our current pipeline. We’d be delighted to explore potential partnerships and discuss your projects with you to identify where we can deliver specific value.
Xentria's Pipeline
XTMAB-16
XTMAB-16
This chimeric human-murine anti-tumor necrosis factor α (TNFα) is being developed as a novel biologic product specifically for the treatment of sarcoidosis. The monoclonal antibody targets the inflammatory response known to occur in patients living with this rare disease. TNFα is a pro-inflammatory cytokine released by immune cells that may promote the formation of harmful granulomas and fibrosis throughout the body of people with the condition. To date, strong early data supports this lead candidate as a potential next-generation treatment for this chronic, multisystem inflammatory disorder.
Meitheal Pharmaceuticals to commercialize novel biologic XTMAB-16 for pulmonary sarcoidosis in North America.
Proposed Mechansim
Of Action
expression system
(monoclonal antibody)
TNF-α inhibitor
Granuloma growth
activated
presenting
cell TCR
activated
presenting
cell TCR
Pro-inflammatory cytokines IL-1, IL-2, TNF-α, IFN-γ
Macrophage
Th1 Cell
Granuloma persistent
expression system
XTMAB-16(monoclonal antibody)
TNF-α inhibitor
*Biopharma Dealmakers (Biopharm Deal)
ISSN 2730-6283 (online)
Co-Developmental Partnerships
LNP Technology & samRNA Platform
LNP Technology & samRNA Platform
This proprietary lipid nanoparticle (LNP) technology held by SunVax leverages their extensive self-amplifying mRNA (samRNA) platform and creates powerful possibilities for the advancement of immuno-oncology (IO) including chimeric antigen receptors (CAR) T cell therapy, vaccines, rare and autoimmune diseases.
The potential use of samRNA in IO involves delivery of RNA molecules, using the LNP system, encoding for tumor antigens or immune-stimulatory proteins to induce an immune response against cancer cells. The direct delivery of samRNA into host cells allows for targeted delivery of the RNA molecule, which may enhance the immune response against cancer cells and improve patient outcomes.
SunVax continues to explore additional opportunities to leverage their enhanced platform with partners who wish to explore LNP-optimization for a specific payload or seek access to SunVax's platforms and technologies for research development. samRNA therapy offers an adaptable platform to build for the future of precision medicine and has the potential to improve the efficacy of cancer treatments and ultimately benefit patients. Research remains ongoing to fully understand the safety and efficacy of samRNA in immuno-oncology applications.
LTD-23
LTD-23
This targeting ligand conjugated to a fluorescent near infrared (NIR) dye aims to selectively bind to overly expressed proteins for the intraoperative visualization of key cancer-cells. By targeting and binding to cancer cells, the Ligand-Targeted Drug (LTD) technology could be used to highlight and distinguish cancer cells from healthy tissue during surgery. This technique can help surgeons to identify and remove cancerous tissue more accurately, potentially improving patient outcomes. Overall, this approach represents an exciting development in the field of cancer imaging and surgery and has the potential to improve the accuracy and efficacy of cancer treatment.
R&D
Mab-22
Insulin Aspart
Insulin Glargine
Insulin Lispro
Filgrastim
Peg Filgrastim
Class of Drugs:
Biosimilars
Partner:
